RxDoctor Payments Data

Majed Dasouki, MD

Clinical Genetics (M.D.) · Kansas City, MONPI 1568454981

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (53.6%), food and beverage and education — rather than concentrated in one kind of arrangement. Modernatx, Inc. accounts for 70.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $1,674 and has fallen 91.2% since, to $147 in 2025.

$2,229in general payments, 2019–2025

Across 23 payments — averaging $96.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$2K
  • Biomarin Pharmaceutical Inc.$426
  • Springworks Therapeutics, Inc.$122
  • Acadia Pharmaceuticals Inc$71
  • Alnylam Pharmaceuticals Inc.$29
$58,789in research payments, 2019–2025

Across 11 payments — averaging $5344.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$41K
  • Modernatx, Inc.$18K

What the payments were for

  • Travel & lodging$1,19454%
  • Food & beverage$66730%
  • Education$36817%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical genetics (m.d.) providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,997
Medicare patients
25
Services billed
26

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical genetics (m.d.) in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →